Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug sales
Pharma
Regeneron has few answers for declining sales of Eylea HD
Regeneron had little explanation for a decline in sales of Eylea HD from $392 million in 2024's third quarter to $305 million in the fourth quarter.
Kevin Dunleavy
Jan 14, 2025 10:25am
Roche projected to claim pharma's 2025 sales crown: Evaluate
Jan 3, 2025 1:07pm
Madrigal's MASH drug Rezdiffra 'blew away' expectations in Q3
Oct 31, 2024 3:24pm
Gardasil's troubles in China haunt Merck in Q3
Oct 31, 2024 1:25pm
Amgen reaps Horizon buyout rewards in Q3, preps biosim launches
Oct 31, 2024 7:50am
J&J leans on oncology growth drivers as Stelara sales slow
Oct 15, 2024 11:45am
